But it is mainly due to the revolutionary impact of anti-HER-2 therapy in breast cancer patients that the role of HER-2 and its blockade has been evaluated also in other tumor types, including gastric and colorectal cancers (CRC). Here, ERBB2 is linked to neoplasm.